Success Metrics

Clinical Success Rate
90.9%

Based on 40 completed trials

Completion Rate
91%(40/44)
Active Trials
0(0%)
Results Posted
35%(14 trials)
Terminated
4(9%)

Phase Distribution

Ph not_applicable
2
4%
Ph phase_3
7
15%
Ph phase_1
11
23%
Ph phase_2
16
34%
Ph phase_4
10
21%

Phase Distribution

11

Early Stage

16

Mid Stage

17

Late Stage

Phase Distribution46 total trials
Phase 1Safety & dosage
11(23.9%)
Phase 2Efficacy & side effects
16(34.8%)
Phase 3Large-scale testing
7(15.2%)
Phase 4Post-market surveillance
10(21.7%)
N/ANon-phased studies
2(4.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.0%

40 of 46 finished

Non-Completion Rate

13.0%

6 ended early

Currently Active

0

trials recruiting

Total Trials

47

all time

Status Distribution
Completed(40)
Terminated(6)
Other(1)

Detailed Status

Completed40
Terminated4
Withdrawn2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
47
Active
0
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Phase 111 (23.9%)
Phase 216 (34.8%)
Phase 37 (15.2%)
Phase 410 (21.7%)
N/A2 (4.3%)

Trials by Status

withdrawn24%
completed4085%
terminated49%
unknown12%

Recent Activity

0 active trials
Showing 5 of 47
completedphase_4

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation

NCT00685061
completedphase_4

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

NCT01172418
completedphase_4

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation

NCT00681343
completedphase_1

Phase I/II Thymus Transplantation With Immunosuppression #950

NCT00579527
completedphase_4

CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation

NCT00246129
View all 47 trials

Clinical Trials (47)

Showing 20 of 47 trialsScroll for more
NCT00685061Phase 4

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation

Completed
NCT01172418Phase 4

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

Completed
NCT00681343Phase 4

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation

Completed
NCT00579527Phase 1

Phase I/II Thymus Transplantation With Immunosuppression #950

Completed
NCT00246129Phase 4

CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation

Completed
NCT00001962Phase 2

A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure

Terminated
NCT00006350Phase 2

Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed
NCT02881567Phase 3

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

Terminated
NCT00275509Phase 3

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

Completed
NCT00080431Phase 1

Daclizumab to Treat HIV-Infected Patients

Completed
NCT00078689Phase 1

Daclizumab and Sirolimus to Treat Uveitis

Completed
NCT00326508Phase 2

Combination Daclizumab/Denileukin Diftitox to Treat Uveitis

Completed
NCT00070759Phase 2

Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis

Completed
NCT00071838Phase 2

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

Completed
NCT00014911Phase 2

Islet Transplantation for Type 1 Diabetes

Completed
NCT00130637Phase 2

Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis

Completed
NCT00053976Phase 3

Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease

Completed
NCT00141037Phase 1

Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

Completed
NCT02554955Phase 4

A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants

Completed
NCT00023231Not Applicable

Pediatric Kidney Transplant Without Calcineurin Inhibitors

Completed

Drug Details

Intervention Type
DRUG
Total Trials
47